29. Stein WD, Yang J, Bates SE, Fojo T: Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008, 13(10):1055- 1062. 30. Stein WD, Wilkerson J, Kim ST, Huang X, Fojo AT, Motzer RJ, Bates SE: Analyzing the pivotal trial that compared sunitinib and interferon alfa in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012.